{"id":36950,"date":"2019-03-06T08:00:00","date_gmt":"2019-03-06T06:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&p=36950"},"modified":"2023-09-06T18:45:56","modified_gmt":"2023-09-06T16:45:56","slug":"ipsen-to-present-improvements-to-somatuline-autogel-pre-filled-syringe-at-the-16th-european-neuroendocrine-tumor-society-enets-annual-conference","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-to-present-improvements-to-somatuline-autogel-pre-filled-syringe-at-the-16th-european-neuroendocrine-tumor-society-enets-annual-conference\/","title":{"rendered":"Ipsen to Present Improvements to Somatuline\u00ae Autogel\u00ae Pre-filled Syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference"},"content":{"rendered":"

ENETS abstract coincides with first European launch<\/b><\/p>\n

Paris (France), 6 March 2019 <\/b>\u2013<\/b> Ipsen (Euronext: IPN; ADR: IPSEY) today simultaneously announced the EU launch of a new pre-filled syringe for Somatuline<\/b>\u00ae<\/b> Autogel<\/b>\u00ae<\/b> (lanreotide) for patients with neuroendocrine tumors (NETs), acromegaly or symptoms associated with carcinoid syndrome, and released findings from the human factor studies that underpinned its development as a poster presentation (Abstract #H14) at ENETS 2019.<\/b>1,2<\/b> As of April 2019, patients in Ireland will be the first to benefit from the new ready-to-use, pre-filled syringe. Ipsen has confirmed they are committed to making this new pre-filled syringe available to patients and healthcare professionals throughout Europe, the U.S., Canada, Australia and New Zealand during 2019 following necessary regulatory approvals.
\nThe new pre-filled syringe for Somatuline\u00ae Autogel\u00ae was the result of several studies, involving patients, their caregivers, nurses and other healthcare professionals, to inform and test enhancements to the existing pre-filled syringe.1 Notable new features are modified ergonomics and handling, a needle shield removal system, an injection process with plunger support and heightened ease of use.1 The automatic, built-in safety system, which helps to prevent needle stick injury by locking in place following the administration, has not been changed.<\/p>\n

\u201cToday\u2019s announcement around the EU launch of a new pre-filled syringe for Somatuline\u00ae Autogel\u00ae<\/em> is not only an important new option for<\/em> patients living with acromegaly and NETs but represents a significant milestone in our commitment to patient-centric innovation<\/em>,\u201d said Bartek Bednarz, Senior Vice President, Global Oncology Franchise at Ipsen. \u201cWe are also proud to be sharing<\/em> as a poster presentation at ENETS 2019<\/em> the results of several studies, where we tested, evolved and validated changes for every stage of the Somatuline\u00ae Autogel\u00ae injection experience\u201d, <\/em>added Sotirios Stergiopoulos, Chief Medical Officer at Ipsen.<\/p><\/blockquote>\n

\u201cNETs and acromegaly can be associated with a number of uncomfortable and unpleasant symptoms, so any innovation that eases the physical challenges of treatment for the patient and their healthcare team is a step forward,\u201d<\/em> said Daphne T Adelman, Clinical Nurse Specialist from Northwestern University in Chicago, U.S. and one of the authors of the study.<\/p><\/blockquote>\n

Attachment<\/strong><\/p>\n